Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Appaloosa Management Sold Entire Stake In American Airlines Group; ASML Holding; Delta Air Lines; Deutsche Bank; Goodyear Tire & Rubber Company; IQVIA Holdings; Mohawk Industries; Owens Corning; Taiwan Semiconductor Manufacturing Company; United Airlines Holdings.

2026-05-15
- 13F Filing

Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative?

2026-05-15
Earlier this week, IQVIA Holdings announced an expanded collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program using its AI-enabled clinical trial capabilities across design, site selection and execution. This partnership highlights how IQVIA is using integrated data, analytics and clinical expertise to help biopharma clients execute complex international biosimilar strategies under a single coordinated framework. Next,...

IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions

2026-05-15
IQVIA’s first quarter results were positively received by the market, reflecting stronger-than-expected revenue growth and solid execution in both its Commercial and R&D Solutions segments. Management attributed this outperformance to increased client demand across core offerings, particularly in areas integrating artificial intelligence and analytics. CEO Ari Bousbib highlighted that, “our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D So

The Broyhill Q1 2026 Portfolio Strategy And Positioning

2026-05-15
Broyhill Asset Management details its Q1 2026 performance and portfolio shifts, highlighting major contributors and new positions. Read the full analysis for more details.

Veeva Systems Expands AI and Vault CRM Momentum: Time to Buy or Hold?

2026-05-14
VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows.

IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities

2026-05-13
RESEARCH TRIANGLE PARK, N.C., May 13, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales

IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

2026-05-13
IQVIA Holdings Inc. (IQV) Bank of America Global Healthcare Conference 2026 May 13, 2026 1:40 PM EDTCompany ParticipantsMichael Fedock - Executive VP &...

IQVIA Advances Strategic Collaboration With Kexing Biopharm To Support Global, Multi-Product Biosimilar Development And Commercialization Program

2026-05-13
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with

Can Veeva Systems' Expanding Partnerships Drive Further Upside?

2026-05-13
VEEV is expanding partnerships, growing Vault CRM adoption and boosting AI capabilities with its Ostro acquisition.

Transcript : IQVIA Holdings Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10

2026-05-13
Presenter SpeechUnknown Analyst I'm on the Bank of America Life Science Tools and Diagnostics team. I'm excited to be hosting IQVIA for our next fireside chat. I'm joined by Michael Fedock, Chief...